WO2023039373A3 - Crispr-cas effector polypeptides and method of use thereof - Google Patents
Crispr-cas effector polypeptides and method of use thereof Download PDFInfo
- Publication number
- WO2023039373A3 WO2023039373A3 PCT/US2022/075980 US2022075980W WO2023039373A3 WO 2023039373 A3 WO2023039373 A3 WO 2023039373A3 US 2022075980 W US2022075980 W US 2022075980W WO 2023039373 A3 WO2023039373 A3 WO 2023039373A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- present disclosure
- crispr
- cas effector
- nucleic acid
- disclosure provides
- Prior art date
Links
- 239000012636 effector Substances 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 6
- 108020004707 nucleic acids Proteins 0.000 abstract 6
- 150000007523 nucleic acids Chemical class 0.000 abstract 6
- 102000004389 Ribonucleoproteins Human genes 0.000 abstract 1
- 108010081734 Ribonucleoproteins Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present disclosure provides CRISPR-Cas effector polypeptides, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising a CRISPR-Cas effector polypeptide of the present disclosure and a guide nucleic acid. The present disclosure provides methods of modifying a target nucleic acid, using a CRISPR-Cas effector polypeptide of the present disclosure and a guide nucleic acid. The present disclosure provides methods of detecting a target nucleic acid, using a CRISPR-Cas effector polypeptide of the present disclosure of the present disclosure and a guide nucleic acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163241859P | 2021-09-08 | 2021-09-08 | |
US63/241,859 | 2021-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023039373A2 WO2023039373A2 (en) | 2023-03-16 |
WO2023039373A3 true WO2023039373A3 (en) | 2023-08-31 |
Family
ID=85506855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/075980 WO2023039373A2 (en) | 2021-09-08 | 2022-09-06 | Crispr-cas effector polypeptides and method of use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023039373A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190351074A1 (en) * | 2017-02-07 | 2019-11-21 | The Regents Of The University Of California | Gene therapy for haploinsufficiency |
WO2020181101A1 (en) * | 2019-03-07 | 2020-09-10 | The Regents Of The University Of California | Crispr-cas effector polypeptides and methods of use thereof |
US20210093667A1 (en) * | 2017-06-26 | 2021-04-01 | The Broad Institute, Inc. | Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
-
2022
- 2022-09-06 WO PCT/US2022/075980 patent/WO2023039373A2/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190351074A1 (en) * | 2017-02-07 | 2019-11-21 | The Regents Of The University Of California | Gene therapy for haploinsufficiency |
US20210093667A1 (en) * | 2017-06-26 | 2021-04-01 | The Broad Institute, Inc. | Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
WO2020181101A1 (en) * | 2019-03-07 | 2020-09-10 | The Regents Of The University Of California | Crispr-cas effector polypeptides and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
AL-SHAYEB BASEM, SKOPINTSEV PETR, SOCZEK KATARZYNA M., STAHL ELIZABETH C., LI ZHENG, GROOVER EVAN, SMOCK DYLAN, EGGERS AMY R., PAU: "Diverse virus-encoded CRISPR-Cas systems include streamlined genome editors", CELL, ELSEVIER, AMSTERDAM NL, vol. 185, no. 24, 1 November 2022 (2022-11-01), Amsterdam NL , pages 4574 - 4586.e16, XP093088536, ISSN: 0092-8674, DOI: 10.1016/j.cell.2022.10.020 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023039373A2 (en) | 2023-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023003255A (en) | Crispr-cas effector polypeptides and methods of use thereof. | |
MX2022007858A (en) | Crispr-cas effector polypeptides and methods of use thereof. | |
PH12021551114A1 (en) | Crispr-cas12j enzyme and system | |
PH12019501413A1 (en) | T-cell modulatory multimeric polypeptides and method of use thereof | |
WO2020102741A8 (en) | Methods and compositions for protein sequencing | |
WO2020028555A3 (en) | Novel crispr enzymes and systems | |
WO2020123887A3 (en) | Novel crispr-cas systems for genome editing | |
AU2017266905A1 (en) | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof | |
MX2022005328A (en) | Compositions and methods for rna-encoded dna-replacement of alleles. | |
WO2017151818A3 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
WO2017151940A3 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
WO2023049742A3 (en) | Engineered casx repressor systems | |
WO2020030984A3 (en) | Compositions and methods for genome engineering with cas12a proteins | |
WO2015130846A3 (en) | Compositions and methods for the site-specific modification of polypeptides | |
WO2023102329A3 (en) | Effector proteins and uses thereof | |
JOP20200323A1 (en) | Methods of manufacturing amino acid compositions | |
WO2016130628A8 (en) | Griffithsin mutants | |
PL415888A1 (en) | Method for producing insulin and its derivatives and the hybrid peptide used in this method | |
WO2020108629A8 (en) | Polypeptide rdp1 and purification method and use therefor | |
WO2023039373A3 (en) | Crispr-cas effector polypeptides and method of use thereof | |
WO2019229064A3 (en) | Method for producing albicanol compounds | |
MY197497A (en) | Anti-pd-l1 antibody for detecting pd-l1 | |
PH12020500087A1 (en) | Immunogenic compositions comprising cea muc1 and tert | |
WO2023147240A3 (en) | Variant type v crispr/cas effector polypeptides and methods of use thereof | |
WO2023130022A3 (en) | Cystatin rna compositions for tissue engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22868241 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |